Beckman Coulter Life Sciences Acquires Blue Ocean Biomedical

With the acquisition of Blue Ocean Biomedical, Beckman Coulter Life Sciences LLC has added low complexity analysers that integrate automated sample preparation and directly address emerging flow cytometry market trends to its range of instruments.
Driving growth through internal product development and through acquisition of differentiated businesses and technologies remains a core strategy for Beckman Coulter and Blue Ocean Biomedical’s products complement the company’s cytometry portfolio with instruments based on a “sample in, result out” (SIRO) approach that represents a fundamental change in the routine clinical analysis sector.
“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president, Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”

“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go™’ flow cytometers,” said Mike Brochu, CEO and co-founder of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”
The systems and reagents are currently for distribution in the European Union only.